asco 2013: pdl1 inhibitors in melanoma
Published 11 years ago • 231 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
6:24
asco 2013: nivolumab blocking pd1 in lung cancer and melanoma
-
4:15
asco 2013: selumetinib, the first effective drug for advanced melanoma of the eye
-
5:26
checkpoint inhibitor therapy for treating melanoma
-
3:57
asco 2013: role of microenvironment and stroma in cancer therapy
-
10:39
developments with pd1 and immunotherapy in melanoma
-
5:37
pd-1 inhibitor use in melanoma
-
59:56
melanoma highlights from asco
-
9:02
pd1/ ctla4 : upfront or sequentially?
-
2:10
developments in pd-1 and pd-l1 inhibitors presented at asco 2016
-
5:03
anti-pd-1 drug nivolumab shows high and durable clinical activity in advanced melanoma
-
1:27
dr. antoni ribas on anti-pd-1 agent lambrolizumab in advanced melanoma
-
5:30
what is the relationship between pd-l1 expression and antitumor activity?
-
2:11
asco lung cancer highlights, pt 13: immune checkpoint inhibitor mpdl3280a in advanced nsclc
-
59:45
melanoma highlights from asco 2020
-
1:52
comment: pd-1 targeting mk-3475 gives long-term responses in melanoma
-
2:11
melanoma retreatment with anti-pd1 therapy
-
1:52
what are checkpoint inhibitors
-
3:49
pd-l1/cd8 expression and outcomes in melanoma patients who received dabrafenib/trametinib